The PFO Occluder is indicated to reduce the risk of recurrent ischemic stroke in patients—predominantly between the ages of 18 and 60 years—who have had a cryptogenic stroke due to a presumed paradoxical embolism as determined by a neurologist and cardiologist following an evaluation to exclude known causes of ischemic stroke.
Among patients with a patent foramen ovale (PFO), the Amplatzer PFO Occluder has demonstrated excellent safety and efficacy in reducing the risk of recurrent stroke.
For patients who have experienced cryptogenic stroke, the thought of a recurrence can generate anxiety. For patients’ peace of mind, the importance of determining and delivering the most effective treatment cannot be overemphasized.
Back to Walking 12 Miles per DayAlan Whitstable - England
As an employee of the Royal Mail postal service “I’m back on full delivery, walking nearly 12 miles a day. Now it gets to be 8:00 at night and I’m still bouncing off the walls full of energy. I feel that I owe everyone who was involved a massive thank you.”
AP2947037-WBO Rev. A